Trial Profile
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2011
Price :
$35
*
At a glance
- Drugs Gemigliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 24 Sep 2010 Results were reported at the 46th Annual Meeting of the European Association for the Study of Diabetes.
- 13 Jul 2010 New trial record
- 25 Jun 2010 Results have been presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA 2010).